West Pharmaceutical Services Inc. revenue $872.30M, quarter ended Jun 30, 2026
West Pharmaceutical Services Inc. reported $872.30M of revenue in the quarter ended Jun 30, 2026, +13.8% on the quarter ended Jun 30, 2025. Across the six months ended Jun 30, 2026, $1.72B, +17.3% on the six months ended Jun 30, 2025.
Quarterly revenue, quarter ended Jun 30, 2026 $872.30M +13.8% year over year +$105.80M against $766.50M for the quarter ended Jun 30, 2025
Six months ended Jun 30, 2026 $1.72B +17.3% JMM's sum of the 2 contiguous quarters below, 181 days end to end, each one accession-linked. Measured against the $1.46B of the six months ended Jun 30, 2025.
Every WST quarter JMM stores, on a real time axis
Which quarters built the six months ended Jun 30, 2026, and which carried the change
- Quarter ended Mar 31, 2026 $844.9M against $698.0M for the quarter ended Mar 31, 2025 +$146.9M 58% of the change 10-Q
- Quarter ended Jun 30, 2026 $872.3M against $766.5M for the quarter ended Jun 30, 2025 +$105.8M 42% of the change 10-Q
What the WST record says, and what to quote from it
Growth is slowing, from +21.0% for the quarter ended Mar 31, 2026 to +13.8%.
The last 5 comparable prints run +0.4%, +9.2%, +7.7%, +21.0%, +13.8%, so the latest rate is 7.2 points below the quarter before it, and the fastest quarter in this run was +21.0% for the period ended Mar 31, 2026. Here is what those points are worth: at +21.0%, the quarter ended Jun 30, 2026 would have printed $927.82M instead of $872.30M. The $55.52M between them is the whole of what decelerating means at this size.
The sequential step, +3.2% from the quarter ended Mar 31, 2026, is mostly this issuer's own seasonality, which is why it is not the headline here and not the headline anywhere serious.
These quarters do not close a fiscal year. SEC builds its quarterly frames from the values a filer tags, and most filers tag no standalone fourth quarter: it is reported inside the annual filing as part of the year. Six months ended Jun 30, 2026 is the largest total they genuinely close, and it is the second figure above. The annual report in WST's filing history carries the year as West Pharmaceutical Services Inc. reports it.
Is this the same legal entity, and who says so
WST has filed under one earlier name
| Name on file | From | Until |
|---|---|---|
| WEST CO INC |
From the issuer's own SEC submissions record. The CIK does not change when the name does, so every filing made under a name above sits in the same filing history as the ones made today, and a search for the old name is a search for this company.
WST quarterly revenue, filing by filing
| Period ended | Quarterly revenue | Year over year | Filed | Evidence |
|---|---|---|---|---|
| 10-Q | $872.3M | +13.8% vs $766.5M, period ended Jun 30, 2025 | Open filing | |
| 10-Q | $844.9M | +21.0% vs $698.0M, period ended Mar 31, 2025 | Open filing | |
| 10-Q | $804.6M | +7.7% vs $746.9M, period ended Sep 30, 2024 | Open filing | |
| 10-Q | $766.5M | +9.2% vs $702.1M, period ended Jun 30, 2024 | Open filing | |
| 10-Q | $698.0M | +0.4% vs $695.4M, period ended Mar 31, 2024 | Open filing | |
| 10-Q | $746.9M | Not stored no quarter one year earlier in the stored set | Open filing | |
| 10-Q | $702.1M | Not stored no quarter one year earlier in the stored set | Open filing | |
| 10-Q | $695.4M | Not stored no quarter one year earlier in the stored set | Open filing |
Every row is the SEC concept RevenueFromContractWithCustomerExcludingAssessedTax, read from
the SEC company facts API by the JMM collector,
checked Aug 10, 2026. The change column is year over year and names the exact period it was measured
against, because these periods are not contiguous: a change against whichever row happens to sit below would compare
quarters up to three years apart. Earlier rows carry the accession SEC attributes the value to, which can be a later
filing that restated the period, so only the most recent row's 23-day gap is a reporting delay.
WST against every other Surgical & Medical Instruments & Apparatus filer JMM covers
- MMM 3M Co.MMM $6.5Bperiod ended Jun 30, 2026
- BSX Boston Scientific Corp.BSX $5.4Bperiod ended Jun 30, 2026
- RMD Resmed Inc.RMD $1.4Bperiod ended Mar 31, 2026
- DXCM Dexcom Inc.DXCM $1.3Bperiod ended Jun 30, 2026
- WST West Pharmaceutical Services Inc.WST, this page $872.3Mperiod ended Jun 30, 2026
Each issuer's latest stored quarter, in USD, for every filer JMM covers under SEC SIC 3841. Fiscal calendars differ, so these periods end on different dates: the bars compare scale, not a shared quarter. Coverage is JMM's, not the classification's, so this is not the whole industry.
Continue from the West Pharmaceutical Services Inc. record
Reproduce any row in the table below from the raw XBRL frames, period by period.
CalculatorAnnualize the growth between any two of these quartersPaste a starting and ending value from the table to get a compound annual rate, before and after CPI-U inflation.
GuideWhat the XBRL tag behind this figure actually measuresWhy two issuers reporting the same business can carry different revenue concepts, and what that changes about comparing them.